Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
PDSB Stock Chart & Stats
$0.87
-$0.09(-5.36%)
At close: 4:00 PM EST
$0.87
-$0.09(-5.36%)
Day’s Range― - ―
52-Week Range$0.70 - $2.28
Previous CloseN/A
Volume197.50K
Average Volume (3M)1.02M
Market Cap
$48.93M
Enterprise Value$39.11M
Total Cash (Recent Filing)$26.20M
Total Debt (Recent Filing)$17.97M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Mar 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding54,721,306
10 Day Avg. Volume461,938
30 Day Avg. Volume1,017,606
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.59K
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$9.00Price Target Upside934.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySITC mechanistic data help explain PDS’s strong clinical efficacy, showing PDS0101 activates key immune pathways and generates response-linked signatures.
Clinical Trial StrategyPivoting to PFS-based strategy to expedite PDS0101 approval.
Regulatory StrategyPDS plans to seek an expedited approval pathway for PDS0101 in HPV16+ head and neck cancer, following strong data from the VERSATILE-002 trial.
Bears Say
PDS Biotechnology News
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $0.70 and its highest was $2.28 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $48.93M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Mar 26, 2026 which is in 109 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Nov 13, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.197 by $0.007.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.2.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 54,721,306 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.197. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (934.48% Upside)
$9.00 (934.48% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.5%
Last 30 Days ▼ 26.6%
Last 30 Days ▼ 26.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.41%
12-Months-Change
Fundamentals
Return on Equity
-221.81%
Trailing 12-Months
Asset Growth
-33.83%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
PDSB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with significant achievements in clinical trial progress and strategic amendments to enhance regulatory approval processes. However, financial challenges and a temporary trial pause highlight ongoing operational and funding hurdles.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$9.00
▲(934.48% Upside)
Technical Analysis
Tempest Therapeutics
―
Mersana Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
1.79% Insiders
5.21% Mutual Funds
0.91% Other Institutional Investors
88.50% Public Companies and
Individual Investors